PER-019-18已完成未知
PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED STUDY OF AERUCIN® ASADJUNCT THERAPY TO ANTIBIOTICS IN THE TREATMENT OF P. AERUGINOSAPNEUMONIA
Aridis Pharmaceuticals, Inc,0 个研究点目标入组 0 人开始时间: 2018年10月17日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Written Informed Consent given by the patient or, if not possible, by a legally authorized representative and/or an independent physician as authorized by the competent ethics committee (EC) or independent review board (IRB) and local regulations.
- •2. Diagnosis of pneumonia based on the following criteria:see protocol, pg 6
排除标准
- •1. The subject is moribund.
- •2. Effective antibacterial drug therapy for the index pneumonia administered continuously for 48 hours or more prior to initiation of study treatment.
- •For further criteria, see protocol pg 7
研究者
相似试验
已完成
不适用
DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING DOSES AND THE EFFECT OF FOOD ON ORAL WCK 4873 IN HEALTHY ADULT VOLUNTEERSBacterial PneumoniaRespiratory Tract Infections10024970NL-OMON38693Wockhardt Bio AG78
已完成
不适用
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, IN PARALLEL GROUPS, MULTICENTER, TO EVALUATE EFFICACY AND SAFETY IN TREATMENT REPEATED WITH TEGASEROD 6 MG TWICE PER DAY AND PLACEBO IN WOMEN WITH IRRITABLE BOWEL SYNDROME COPER-076-02OVARTIS BIOSCIENSES PERU S.A.,
已完成
不适用
A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa (Activated)-A41 Other sepsisOther sepsisA41PER-017-04ELI LILLY INTERAMERICA INC.,
已完成
3 期
RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE, EFFICACY, SAFETY AND TOLERABILITY OF EPA-FFA GASTRO-RESISTANT CAPSULES, IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS (FAP)FAPhereditary development of polyps in colon1001801810017991NL-OMON55587SLA Pharma30
进行中（未招募）
不适用
A STUDY OF THE MAINTENANCE OF EFFICACY OF ETANERCEPT PLUS DMARD(S)COMPARED WITH DMARD(S) ALONE IN SUBJECTS WITH RHEUMATOID ARTHRITIS AFTER ACHIEVING AN ADEQUATE RESPONSE WITHETANERCEPT PLUS DMARD(S)Rheumatoid ArthritisEUCTR2011-005448-87-HUPfizer Inc, 235 East 42nd Street, New York, NY 10017320